Lysosomal storage diseases (LSDs) comprise a large group of monogenic, metabolic disorders caused by deficiency of lysosomal hydrolases. Accumulation of intermediate metabolites in lysosomes affects systemic organs and the central nervous system (CNS). However, it is still largely unknown how an impaired lysosomal system influences cellular homeostasis and ultimately leads to organ dysfunction. The poor understanding of pathogenesis adds to the challenge in finding a treatment for LSDs that would be effective for both systemic and CNS disease. The long-term objective of the proposed research is to achieve a comprehensive evaluation of the CNS dysfunction that occurs in galactosialidosis (GS; protective protein/cathepsin A [PPCA deficiency] and GM1-gangliosidosis (GM1; beta-galactosidase [b-gal deficiency]). This knowledge will allow us to assess the feasibility, limitations, and effectiveness of specific therapies. To accomplish our goal, we have developed mouse models of cells that overexpress the correcting enzyme in a lineage specific manner effectively restore systemic organ function in GS mice, but only could partially ameliorate severely affected area of the CNS, such as the cerebellum. As a step toward developing more effective therapies for the CNS disease, we propose the following aims:
Aim 1. We will complete our ongoing studies of the phenotypes of GS and GM1 mice so that the pathogenesis of neurodegeneration can be elucidated. The combined use of histological staining and immunocytochemistry with antibodies to cellular and molecular markers for neurons and glia will enable us to determine the status and characteristics of cells at disease sites, and during disease progression.
Aim 2. We will generate transgenic mice in which expression of the therapeutic proteins (PPCA or beta gal) is targeted to neurons and glia by using cell-specific promoters. These transgenic models will be crossed with the respective null mice. This approach will allow us to assess the efficacy of neural cells to produce and secrete PPCA and beta-gal and of affected neighboring cells to take up the enzymes.
Aim 3. We will perform ex vivo gene transfer using genetically modified, deficient BM cells for syngeneic BMT of GS and GM1. This approach will create the most realistic scenario to gene therapy in the patients. In parallel, we will determine the efficacy of in vivo administration of a recombinant adeno-associated virus (rAAV) expressing the enzymes in correcting difficult to treat CNS regions. These combined studies should provide a solid base for the development of feasible cure for these diseases, leading to clinical treatments that have a greater chance of success and a lower risk of adverse effects.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
2R01DK052025-05A2
Application #
6548653
Study Section
Special Emphasis Panel (ZRG1-SSS-2 (01))
Program Officer
Mckeon, Catherine T
Project Start
1997-07-01
Project End
2005-05-31
Budget Start
2002-07-01
Budget End
2003-05-31
Support Year
5
Fiscal Year
2002
Total Cost
$318,750
Indirect Cost
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Regier, Debra S; Proia, Richard L; D'Azzo, Alessandra et al. (2016) The GM1 and GM2 Gangliosidoses: Natural History and Progress toward Therapy. Pediatr Endocrinol Rev 13 Suppl 1:663-73
Campos, Yvan; Qiu, Xiaohui; Gomero, Elida et al. (2016) Alix-mediated assembly of the actomyosin-tight junction polarity complex preserves epithelial polarity and epithelial barrier. Nat Commun 7:11876
Machado, Eda; White-Gilbertson, Shai; van de Vlekkert, Diantha et al. (2015) Regulated lysosomal exocytosis mediates cancer progression. Sci Adv 1:e1500603
Neves, Juliana de Carvalho; Rizzato, Vanessa Rodrigues; Fappi, Alan et al. (2015) Neuraminidase-1 mediates skeletal muscle regeneration. Biochim Biophys Acta 1852:1755-64
Katorcha, Elizaveta; Klimova, Nina; Makarava, Natallia et al. (2015) Loss of Cellular Sialidases Does Not Affect the Sialylation Status of the Prion Protein but Increases the Amounts of Its Proteolytic Fragment C1. PLoS One 10:e0143218
Annunziata, Ida; Patterson, Annette; d'Azzo, Alessandra (2015) Isolation of mitochondria-associated ER membranes (MAMs) and glycosphingolipid-enriched microdomains (GEMs) from brain tissues and neuronal cells. Methods Mol Biol 1264:25-33
d'Azzo, Alessandra; Machado, Eda; Annunziata, Ida (2015) Pathogenesis, Emerging therapeutic targets and Treatment in Sialidosis. Expert Opin Orphan Drugs 3:491-504
Bonten, Erik J; Annunziata, Ida; d'Azzo, Alessandra (2014) Lysosomal multienzyme complex: pros and cons of working together. Cell Mol Life Sci 71:2017-32
Bonten, Erik J; Yogalingam, Gouri; Hu, Huimin et al. (2013) Chaperone-mediated gene therapy with recombinant AAV-PPCA in a new mouse model of type I sialidosis. Biochim Biophys Acta 1832:1784-92
Annunziata, Ida; Patterson, Annette; Helton, Danielle et al. (2013) Lysosomal NEU1 deficiency affects amyloid precursor protein levels and amyloid-? secretion via deregulated lysosomal exocytosis. Nat Commun 4:2734

Showing the most recent 10 out of 35 publications